In quest to leapfrog Pfizer, Peninsula vaccine company gets $85 million injection

The company is pushing into clinical trials for its experimental broad-spectrum vaccine against a bacterium that causes pneumonia and bloodstream infections.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.